U.S. Stock Insider Trading | PROCEPT BioRobotics disclosed two insider trading transactions on March 12.

robot
Abstract generation in progress

On March 12, 2026, PROCEPT BioRobotics (PRCT) disclosed two transactions involving company insiders. Executive Nouri Alaleh sold 3,098 shares on March 10, 2026.

[Recent Insider Transactions]

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/US$ Total Amount/US$
Mar 12, 2026 Executive Nouri Alaleh Mar 10, 2026 Sell 3,098 25.60 79.30k
Mar 12, 2026 Executive Nouri Alaleh Mar 10, 2026 Sell 145 26.74 3,877.00
Mar 9, 2026 Director Desai Antal Rohit Mar 9, 2026 Buy 1,300 25.42 33.00k
Mar 9, 2026 Director Desai Antal Rohit Mar 6, 2026 Buy 106,000 23.33 2.4857 million
Mar 9, 2026 Director Desai Antal Rohit Mar 6, 2026 Buy 53,800 24.10 1.2958 million
Mar 9, 2026 Director Desai Antal Rohit Mar 9, 2026 Buy 53,800 24.91 1.3403 million
Mar 9, 2026 Director Desai Antal Rohit Mar 9, 2026 Buy 43,600 24.08 1.0495 million
Mar 9, 2026 Director Desai Antal Rohit Mar 5, 2026 Buy 142,500 25.44 3.6250 million
Mar 9, 2026 Director Desai Antal Rohit Mar 5, 2026 Buy 24,700 26.41 653,500
Mar 9, 2026 Executive Waters Kevin Mar 6, 2026 Sell 6,721 23.70 1.5930 million

[Company Profile]

PROCEPT BioRobotics Corporation was incorporated in 2007 in California. In April 2021, the company was re-incorporated in Delaware. The company is a commercial-stage surgical robotics company, focused on advancing patient care by developing transformative solutions in urology. They develop, manufacture, and sell the AquaBeam robot system, an advanced image-guided surgical robotics system for minimally invasive urological surgeries, initially focused on treating benign prostatic hyperplasia, or BPH.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments